Stefania Salvagni
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report.
Journal: Tumori
Published: January 12, 2026
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.
Journal: Investigational new drugs
Published: July 26, 2021
Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.
Journal: Reviews in endocrine & metabolic disorders
Published: November 24, 2020
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.
Journal: Current heart failure reports
Published: October 07, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 22, 2020
Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.
Journal: Future oncology (London, England)
Published: May 15, 2020
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: April 18, 2020
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
Journal: Cancers
Published: March 23, 2020
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 30, 2019
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 13, 2017
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 04, 2017
Last Updated: 09/26/2026